Synopsis
Randomised, double‐blind, placebo‐controlled phase III trial of oral melatonin for the prevention of delirium in hospital in people with advanced cancer
Research Overview
Delirium is a highly prevalent, medical emergency in advanced cancer. Currently around two thirds of hospitalized people with advanced cancer will have a delirium episode whilst they are in hospital. The primary objective of this study is to determine if oral prolonged release melatonin compared to placebo can increase the number of delirium free days during hospitalization. The aim is to determine if the use of melatonin can reduce the incidence of delirium, reduce delirium severity and duration, positively influence hospital length of stays, reduce patient and family distress and improve sleep quality for the patient. Oral melatonin/placebo is given each evening whilst the patient is an inpatient for a maximum of 21 days.
Key Contact
Name: Centre for Palliative Care
Email: svhm.CPCtrials@svha.org.au
Project Team:
- Ass Prof Jenny Weil
- Prof Jenny Philip
- Dr Beth Russell
- Ass Prof Mark Boughey
- Dr Laura Booth
- Dr Tamsin Bryan
- Dr Maziar Fahandej
- Dr Matt Grant
- Dr Jo-An Seah
- Dr Peter Sherwen
- Dr Sarah Leung
- Indy Khera
- Di Saward
Funding Source:
University of Technology Sydney